Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABHD6 | Q9BV23 | 3/20 | 0.44 |
| ▸ | MGLL | Q99685 | 2/20 | 0.44 |
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.41 |
| ▸ | OXTR | P30559 | 1/20 | 0.41 |
| ▸ | AVPR1A | P37288 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | RORC | P51449 | 8/20 | 0.40 |
| ▸ | STS | P08842 | 1/20 | 0.39 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.38 |
| ▸ | TACR1 | P25103 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31549809 | 1.00 | ABHD6 (0.44) | ABHD6MGLLGPR119OXTRAVPR1A | |
| SCHEMBL31029128 | 0.85 | NR1H2 (0.45) | ABHD6MGLLGPR119OXTRAVPR1A | |
| SCHEMBL21381692 | 0.85 | MAPT (0.47) | GPR119MAPTPOLBRORCSTS | |
| SCHEMBL18357619 | 0.83 | GPR119 (0.47) | GPR119OXTRAVPR1A | |
| SCHEMBL30700632 | 0.82 | RORC (0.42) | ABHD6MGLLGPR119OXTRAVPR1A | |
| SCHEMBL30700814 | 0.82 | MAPT (0.43) | ABHD6MGLLGPR119MAPTRORC | |
| SCHEMBL30490318 | 0.80 | ENPP2 (0.44) | ABHD6MGLLGPR119MAPTRORC | |
| SCHEMBL23850247 | 0.80 | GPR119 (0.49) | ABHD6MGLLGPR119MAPTRORC | |
| SCHEMBL30490344 | 0.78 | F13A1 (0.48) | GPR119MAPTRORCSTSTGFBR1 | |
| SCHEMBL23850532 | 0.77 | RORC (0.55) | ABHD6MGLLMAPTRORCTACR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12577257-B2 | Heterocyclic compounds | HOFFMANN-LA ROCHE INC. (US) | 2026-03-17 | — | — | US | disclosed |
| EP-3883936-B1 | NEW HETEROCYCLIC COMPOUNDS | HOFFMANN LA ROCHE (CH) | 2023-07-12 | — | — | EP | disclosed |
| US-20210387999-A1 | HETEROCYCLIC COMPOUNDS | HOFFMANN-LA ROCHE INC. (US) | 2021-12-16 | — | — | US | disclosed |
| EP-3883936-A1 | NEW HETEROCYCLIC COMPOUNDS | F. Hoffmann-La Roche AG (CH) | 2021-09-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210387999-A1 | HETEROCYCLIC COMPOUNDS | CYP1B1, CYP4B1, CYP4X1 | ABHD6 2881/4885MGLL 1712/4885GPR119 2884/4885 |
| US-12577257-B2 | Heterocyclic compounds | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CBR1, CBR3 | ABHD6 3668/4885MGLL 3086/4885GPR119 2693/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.